Summary
The AI response is largely off-label/irrelevant to FDA prescribing information because most claims are about coupons/savings programs (not addressed in the provided label excerpts). While the medical use-related claims could be label-relevant (cholestyramine for cholesterol and pruritus from partial biliary obstruction), the response does not provide adequate, label-specific substantiation for the “bile-acid–related conditions” phrasing, and it includes non-label content treated as if it were prescribing-information accurate.
Category Scores
Accurate Statements
"Prevalite" is a brand name for cholestyramine.
Supported indirectly by label context provided (Prevalite is cholestyramine for oral suspension, USP). No direct quote in excerpts that says “brand name,” but the label text supplied identifies Prevalite® as cholestyramine for oral suspension, USP powder.
Unsupported Statements
Cholestyramine is used to lower cholesterol.
Not explicitly supported with the full label phrasing in the provided user claims-to-label mapping; label excerpt states Prevalite indicated to reduce elevated serum cholesterol in primary hypercholesterolemia (adjunctive to diet). The response does not specify “primary hypercholesterolemia,” “adjunctive therapy to diet,” or the “not adequately responsive to diet” condition required by the label excerpt.
Cholestyramine is used to treat certain bile-acid–related conditions.
Label excerpt supports relief of pruritus associated with partial biliary obstruction (Section 1) and describes mechanism related to bile acids, but the claim is overly broad/vague (“certain bile-acid–related conditions”) and not limited to the specific labeled indication.
All coupon/discount card claims (e.g., definition of coupon, availability changes by location/date, older cards expired, eligibility groups, pharmacy participation, out-of-pocket vs copay, generic vs brand coupon pricing comparisons, and DrugPatentWatch.com usefulness/limitations).
Not addressed in the provided FDA prescribing information excerpts for Prevalite/cholestyramine. These claims are unrelated to label content and therefore unsupported by the supplied prescribing information.
Generic cholestyramine may be cheaper under a plan than brand cholestyramine with a discount card.
Cost/coverage/coupon/pricing relationships are not discussed in the provided label excerpts; unsupported by prescribing information.
In many cases, generic cholestyramine reduces cost without needing a coupon.
No pricing or comparative cost statements are present in the provided label excerpts; unsupported.
Coupon searches for brand cholestyramine depend on whether generic cholestyramine is cheaper under the plan than the brand with a discount card.
No such comparative pricing/coupon-search logic appears in the provided label excerpts; unsupported.
Generic substitution depends on insurance and the pharmacy’s pricing.
Not discussed in the provided label excerpts; unsupported.
Some coupons are only for certain eligibility groups.
Not discussed in the provided label excerpts; unsupported.
Some coupon results differ because an older card may have expired.
Not discussed in the provided label excerpts; unsupported.
Some coupons work only for pharmacies that participate.
Not discussed in the provided label excerpts; unsupported.
Some discounts apply only when paying out of pocket, not insurance copays.
Not discussed in the provided label excerpts; unsupported.
DrugPatentWatch.com can be useful for checking brand/generic context and related medication details.
Not discussed in the provided label excerpts; unsupported.
DrugPatentWatch.com may not directly list every savings card offer.
Not discussed in the provided label excerpts; unsupported.
Cholestyramine is used to treat certain bile-acid–related conditions.
While pruritus associated with partial biliary obstruction is labeled, the response does not precisely state this indication as written in the label excerpt; claim remains vague/broader than label support.
Contradictions
Important Omissions
For the medical indication claims, the response omits key label qualifiers such as: “adjunctive therapy to diet,” “primary hypercholesterolemia,” and “who do not respond adequately to diet,” and the limitation that cholestyramine is not indicated when hypertriglyceridemia is the abnormality of most concern (Section 1).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided response’s coupon/cost content is not present in the label and therefore is not a direct prescribing-safety claim. However, the medical indication statements are imprecise relative to labeled conditions/qualifiers, which could lead to misunderstandings about appropriate labeled use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims concern coupon/savings-card/pricing logistics that are not addressed in the provided FDA prescribing information. Medical-use claims are also overly broad/vague versus label wording.
Suggested Improvement
Restrict medical indication statements to the specific labeled indications and qualifiers from Section 1 (primary hypercholesterolemia adjunctive to diet; pruritus associated with partial biliary obstruction). Remove or clearly separate non-label coupon/pricing/website assertions since they are unsupported by the provided prescribing information.